Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 16   

Articles published

KYTH 36.51 +0.40 (1.11%)
price chart
Kythera Biopharmaceuticals Inc. (KYTH) Jumps 5.77% on October 23
Kythera Biopharmaceuticals Inc. ($KYTH) was among the biggest gainers on the Russell 2000 for October 23 as the stock popped 5.77% to $36.11, representing a gain of $1.97 per share.
Related articles »  
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
KYTHERA Biopharmaceuticals, Inc. KYTH, +2.91% today announced that on October 17, 2014, the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase an aggregate of 28,500 shares of the ...
Related articles »  
Kythera Biopharmaceuticals Inc. (KYTH) Jumps 5.49% on October 8
Kythera Biopharmaceuticals Inc. (KYTH) was among the biggest gainers on the Russell 2000 for October 8 as the stock popped 5.49% to $32.86, representing a gain of $1.71 per share.
Related articles »  
Drugs Industry Update: Epizyme, Genomic Health, Kythera Biopharma ...
Epizyme, Inc. (NASDAQ:EPZM) : Announced the appointments of Peter Ho, as Chief Development Officer and Michael Shih, as Vice President, Business Development.
Related articles »  
Insider Selling: Nathaniel E. David Unloads 1350 Shares of Kythera ...
... missing the consensus estimate of ($0.83) by $0.03. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.
Insider Selling: Kythera Biopharmaceuticals CEO Unloads 3826 Shares of Stock ...  sleekmoney
Related articles »  
Kythera Biopharmaceuticals Director Sells $44010 in Stock (KYTH)
Analysts expect that Kythera Biopharmaceuticals will post $-3.34 EPS for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription ...
Insider Selling: Kythera Biopharmaceuticals CEO Sells 3826 Shares of Stock ...  Mideast Time
Related articles »  
Active Stocks to Watch: Vodafone Group Plc (ADR) (NASDAQ:VOD), CBD ...
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) has 2.20% insider ownership while its institutional ownership stands at 33.20%.
A Newer Nifty Fifty State Index: Replacements Rule!
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) was projected to net $453.86 based on 1yr. target price estimates from five analysts plus dividends less $20 broker fees.
Provectus Biopharmaceuticals Sees Large Decrease in Short Interest (PVCT)
Provectus Biopharmaceuticals Inc logo Provectus Biopharmaceuticals (NYSE:PVCT) was the recipient of a significant drop in short interest in August.
Related articles »